KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Tax Provisions (2016 - 2025)

Pfizer (PFE) has disclosed Tax Provisions for 17 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions changed N/A to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$266.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$266.0 million for FY2025, 850.0% down from the prior year.
  • Tax Provisions for Q4 2025 was -$2.0 million at Pfizer, up from -$216.0 million in the prior quarter.
  • The five-year high for Tax Provisions was $1.6 billion in Q3 2022, with the low at -$964.0 million in Q4 2023.
  • Average Tax Provisions over 5 years is $219.3 million, with a median of $141.0 million recorded in 2025.
  • The sharpest move saw Tax Provisions soared 208.54% in 2022, then tumbled 370.79% in 2023.
  • Over 5 years, Tax Provisions stood at -$328.0 million in 2021, then skyrocketed by 208.54% to $356.0 million in 2022, then plummeted by 319.1% to -$780.0 million in 2023, then surged by 130.0% to $234.0 million in 2024, then tumbled by 100.85% to -$2.0 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$2.0 million, -$216.0 million, and $141.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.